Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics (NASDAQ: FATE) generates news primarily around clinical trial developments for its iPSC-derived cell therapy programs. As a clinical-stage biotechnology company, news flow centers on data presentations at medical conferences, regulatory interactions, and pipeline advancement milestones.
Key news categories for FATE include clinical trial updates for FT819 and other CAR T-cell candidates, particularly data from autoimmune disease and oncology studies. Conference presentations at hematology, immunology, and cell therapy meetings often contain meaningful clinical updates. Regulatory designations and FDA interactions represent significant catalysts for this development-stage company.
Corporate developments such as leadership changes, strategic partnerships, and financing activities also drive news coverage. Quarterly earnings reports provide operational updates and cash runway guidance critical for evaluating clinical-stage biotechnology companies. Manufacturing and platform technology announcements reflect progress in scaling iPSC-derived cell production.
Investors following FATE should monitor presentations at major scientific conferences including ASGCT, ASH, ACR, and EULAR where clinical data is typically disclosed. SEC filings including 8-K material event reports often contain time-sensitive regulatory and corporate updates. Bookmark this page for consolidated coverage of Fate Therapeutics developments.
Fate Therapeutics reported promising interim results from its FT596 and FT516 clinical programs for relapsed/refractory B-cell lymphoma. Notably, 71% of patients receiving FT596 achieved an objective response, with 50% achieving complete response (CR). In the FT516 program, 73% of patients achieved an objective response, with 55% reaching CR. Both treatments were well-tolerated, without significant adverse events. The company is initiating further dose-expansion cohorts and continuing to assess the treatment regimens' efficacy and safety.
Fate Therapeutics has made significant strides in the development of iPSC-derived therapies, with the first patient treated in the Phase 1 trial of FT819, a groundbreaking CAR T-cell therapy for relapsed/refractory ALL. Interim Phase 1 data for FT516 reveals that 73% of patients achieved objective responses in relapsed/refractory B-cell lymphoma. The company reported Q2 2021 revenue of $13.4 million, with R&D expenses at $48 million. Cash reserves stood at $845.1 million, indicating a solid financial position.
Fate Therapeutics, Inc. (NASDAQ: FATE) has appointed Yuan Xu, Ph.D., as an independent director to its Board of Directors. Dr. Xu has over 25 years of experience in the biopharmaceutical industry, with notable roles including CEO of Legend Biotech. She brings expertise in developing CAR T-cell therapies and will aid Fate in advancing its iPSC-derived NK and T-cell products into clinical development. The move is anticipated to strengthen the company's pipeline and manufacturing efforts as they progress towards commercial approval.
Fate Therapeutics (NASDAQ: FATE) announced the first patient treatment with FT819, an innovative off-the-shelf CAR T-cell therapy targeting CD19+ cancers. This Phase 1 clinical trial will evaluate three dosing regimens for patients with advanced B-cell leukemias and lymphomas. FT819 is derived from a clonal master iPSC line, promising consistent, mass production and broader patient availability. Key study objectives include safety assessments and determining optimal dosing for subsequent Phase 2 trials.
Fate Therapeutics (NASDAQ: FATE) announced a virtual event on August 19, 2021, to present interim Phase 1 clinical data for its FT596 and FT516 programs targeting relapsed/refractory B-cell lymphomas. The event will be accessible via the company’s website. Fate's iPSC product platform allows for the mass production of engineered cell therapies, enhancing treatment efficacy. FT516 is currently in trials as a standalone treatment for acute myeloid leukemia and in combination therapy, while FT596 targets B-cell antigens with promising preclinical results.
Fate Therapeutics (NASDAQ: FATE) has scheduled a conference call and live audio webcast for August 4, 2021, at 5:00 p.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. To participate, dial 800-773-2954 (toll-free) or 847-413-3731 (toll). The event will be accessible on the Company’s website under 'Events & Presentations.'
Fate Therapeutics is focused on developing programmed cellular immunotherapies for cancer, leveraging its proprietary iPSC product platform.
Fate Therapeutics (NASDAQ: FATE) appointed Mark Plavsic, DVM, PhD, RAC as its new Chief Technical Officer. Dr. Plavsic brings over 20 years of global biopharmaceutical experience, overseeing manufacturing and technical operations. His previous roles include CTO at Lysogene and SVP at Torque Therapeutics. The appointment supports Fate's expansion plans for its iPSC product platform and upcoming GMP manufacturing facility. As part of his employment, Dr. Plavsic received stock options and restricted stock units, indicating a commitment to the company's growth and innovation in engineered cell therapies.
Fate Therapeutics reported promising interim Phase 1 results for FT516, an off-the-shelf NK cell therapy for relapsed/refractory B-cell lymphoma, at the ASCO Annual Meeting. Out of 11 patients, 8 achieved an objective response, including 6 complete responses, with no serious adverse events or grade 3+ side effects noted. The ongoing study is currently enrolling in its fourth dose cohort. The favorable safety profile and activity signal potential for future indication-specific cohorts aimed at combining FT516 with CD20-targeted therapies.
Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 1, 2021, at 1:00 p.m. ET, followed by the BofA Securities 2021 Napa Biopharma Virtual Conference on June 15, 2021, at 5:30 p.m. ET. Investors can access live webcasts on the company's website under the 'Events & Presentations' section. Fate Therapeutics focuses on developing innovative cellular immunotherapies using its proprietary iPSC platform.
Fate Therapeutics announced encouraging interim Phase 1 results for its off-the-shelf, iPSC-derived NK cell therapies, FT516 and FT538, in treating relapsed/refractory AML. Of 12 patients, 5 achieved complete leukemic blast clearance, with FT516 showing no dose-limiting toxicities or cytokine-related side effects. Notably, 2 patients from the second dose cohort maintained remission for over six months without further intervention. FT538 demonstrated anti-leukemic activity with one patient achieving a complete response. The studies indicate potential for durable treatments in outpatient settings.
FAQ
What is the current stock price of Fate Therapeutic (FATE)?
What is the market cap of Fate Therapeutic (FATE)?
